One-Year Rezdiffra Data Shows Liver Stiffness Improvement in Up to 93% of Patients
MDGL sits 16% above its 52-week low of $353.54.
Summary
Madrigal released one-year data showing up to 93% of patients had improved or stabilized liver stiffness on Rezdiffra, with up to 72% still on the drug at one year and high adherence. Safety looked clean: only 11% had at least one adverse event, led by diarrhea at 7% and nausea at 4%, consistent with the established label profile. Improvements held regardless of GLP-1 use, and up to 53% of patients were on a GLP-1 — a useful rebuttal to the worry that GLP-1 drugs shrink Rezdiffra's addressable market. This lands two days after the company's first profitable quarter, $55.4 million of net income on $431.3 million of Rezdiffra sales, so it reinforces the durability story behind the launch rather than changing the near-term numbers.
At the time of this announcement, MDGL was trading at $408.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $353.54 to $615.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.